Sarepta’s Duchenne Gene Therapy Shows Sustained Benefit at Three Years
Sarepta Therapeutics has reported three-year data showing slowed disease progression for its gene therapy Elevidys in patients with Duchenne muscular […]
DMD
Sarepta Therapeutics has reported three-year data showing slowed disease progression for its gene therapy Elevidys in patients with Duchenne muscular […]
